Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

[1]  D. Montefiori,et al.  A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.

[2]  D. Montefiori,et al.  Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial , 2022, The Journal of infectious diseases.

[3]  D. Lauffenburger,et al.  mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions , 2022, Science Translational Medicine.

[4]  A. Katzourakis,et al.  Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity , 2022, Nature Reviews Microbiology.

[5]  D. Montefiori,et al.  Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial , 2022, Nature Medicine.

[6]  J. Mascola,et al.  mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron , 2022, Cell.

[7]  J. Mascola,et al.  mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron , 2022, bioRxiv.

[8]  X. Daniell,et al.  Mapping SARS-CoV-2 antigenic relationships and serological responses , 2022, bioRxiv.

[9]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[10]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.

[11]  H. Vennema,et al.  Mapping the antigenic diversification of SARS-CoV-2 , 2022, medRxiv.

[12]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[13]  D. Follmann,et al.  Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge , 2021, The New England journal of medicine.

[14]  Hyeong Mi Kim,et al.  Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study , 2021, Science.

[15]  J. Mascola,et al.  Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.

[16]  J. Tomassini,et al.  Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge , 2021, medRxiv.

[17]  D. Montefiori,et al.  Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis , 2021, Nature Medicine.

[18]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[19]  Andrew L. Phillips,et al.  Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines , 2021, medRxiv.

[20]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[21]  Samuel M. Brown,et al.  Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[22]  Aaron M. Rosenfeld,et al.  Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.

[23]  Andrew L. Phillips,et al.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[24]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[25]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[26]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[27]  M. Miller.  Agency , 2010 .